# HRQOL in Locally Advanced Thyroid Carcinoma

> **NCT05824312** · — · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Thyroid Cancer
- Tyrosine Kinase Inhibitor
- Health Related Quality of Life

## Interventions

- **DRUG:** Tyrosine kinase inhibitor drugs.

## Key facts

- **NCT ID:** NCT05824312
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2025-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824312, "HRQOL in Locally Advanced Thyroid Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05824312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*